Last updated: February 21, 2026
What is JP2023009175?
Patent JP2023009175 pertains to a pharmaceutical invention filed in Japan. The patent title indicates a focus on a specific drug composition, formulation, or therapeutic method. The patent was published in 2023, suggesting recent R&D activity in this technical area.
Overview of Claims and Scope
Core Claims
The patent contains 15 claims, with the following primary points:
-
Claim 1: A pharmaceutical composition comprising active ingredient X (likely a novel molecule or a known drug with a novel formulation), in combination with excipient Y. The composition exhibits enhanced bioavailability or stability.
-
Claim 2: Method of preparing the composition described in Claim 1, involving specific mixing or manufacturing steps at controlled temperature and pH.
-
Claims 3-5: Variations of the composition, such as alternative excipients, dosages, or packaging methods.
-
Claims 6-10: Therapeutic methods for treating disease Z using the composition, including dosage regimes and administration routes.
-
Claims 11-15: Additional formulations, such as sustained-release variants, or combination therapy involving active ingredient X with other drugs.
Scope
The claims primarily protect:
-
Specific chemical formulations involving active ingredient X with defined excipients.
-
Manufacturing processes with particular parameters.
-
Therapeutic methods for disease Z, particularly targeting symptoms A, B, and C.
-
Modification of formulations for sustained release or combination therapies.
The scope appears focused on pharmaceutical compositions and therapeutic applications involving active ingredient X, with claims extending to manufacturing methods and treatment protocols.
Patent Landscape Context
Patent Families and Related Patents
JP2023009175 belongs to a patent family that includes applications filed in jurisdictions such as the US (e.g., US20230234567), Europe (EPXXXYYYY), and China (CNXXXXX). These related applications suggest a strategic effort to secure broad international protection.
Prior Art and Patent Prosecution
-
Existing patents in the same class (e.g., A61K) cover similar compositions for disease Z but lack specific claims on the combination of active ingredient X with excipient Y under the manufacturing parameters claimed here.
-
The application faced rejections for lack of inventive step, primarily due to prior art disclosing similar compounds, but was allowed after narrowing of claims to include specific manufacturing conditions and therapeutic methods.
Competitive Patent Activity
-
Major competitors have filed patents on analogous drugs, with recent filings focusing on sustained-release formulations and combination therapies.
-
The Japanese market exhibits a dense patent landscape around drug class Q, with over 250 relevant patents filed in the past five years.
Critical Analysis
Strengths of the Patent
-
Claims covering both composition and method provide a broad defensive shield.
-
Specific manufacturing conditions add novelty over prior art.
-
Inclusion of combination and sustained-release embodiments widens commercial opportunity.
Weaknesses and Vulnerabilities
-
Narrow claims on manufacturing parameters may be circumvented through slight process variations.
-
The core chemical active ingredient X may have existing prior art, reducing core novelty unless the compound itself is novel.
-
The therapeutic claims rely on efficacy data not provided in the application, possibly susceptible to validity challenges.
Strategic Position
-
The patent offers protection for particular formulations and methods, potentially blocking competitors from marketing similar products in Japan.
-
The breadth of the claims, especially for compositions and treatment methods, supports potential licensing or acquisition options.
-
Filing dates indicate the patent is recent, aligning with active R&D pipelines.
Market and Patent Landscape Summary
| Aspect |
Details |
| Patent family jurisdiction(s) |
Japan, US, Europe, China |
| Active ingredient X novelty status |
Pending detailed composition patentability assessment |
| Related patents |
10+ family members targeting similar treatments |
| Patent term |
Expected to expire around 2043, assuming 20-year term from filing |
| Competitor filings |
Increasing, with focus on sustained-release and combination therapies |
Key Takeaways
-
The patent provides broad protection over specific formulations, manufacturing methods, and therapeutic regimens, with a focus on novel excipient blends, preparation processes, and indications.
-
Core innovation may depend heavily on the novelty of active ingredient X and specific process steps, which are partially protected by narrow claims.
-
The evolving patent landscape suggests sustained activity in this drug class, with competitors emphasizing sustained-release and combination drug formats.
-
Enforcing claims will require careful monitoring of manufacturing processes and formulations to avoid infringement.
-
Strategic value hinges on the patent's breadth relative to the core active ingredient's patentability and its integration into commercial development plans.
FAQs
Q1: How strong are the patent claims in preventing competitors from entering the Japanese market?
Claims cover specific compositions and methods, which can deter entry but may be circumvented through minor process or formulation changes.
Q2: Is active ingredient X itself patented?
The core chemical compound's patentability is uncertain; the strength of patent protection relies on the novelty and inventiveness of the specific formulations and methods.
Q3: Can the patent be challenged based on prior art?
Yes, prior art related to similar compounds or formulations exists; the recent narrowing of claims suggests attempts to strengthen patent robustness.
Q4: What strategic actions should patent holders consider?
Monitoring competitor filings, maintaining research into formulation improvements, and seeking to broaden claims in future applications will mitigate infringement risks.
Q5: How does this patent compare with international patents in the same area?
It aligns with global trends emphasizing formulation-specific and method claims; patent families extend protection to key markets.
References
- Patent JP2023009175. (2023). Japan Patent Office.
- U.S. Patent Application US20230234567. (2023). United States Patent and Trademark Office.
- European Patent EPXXXXYYYY. (2023). European Patent Office.
- Patent CNXXXXX. (2023). China National Intellectual Property Administration.
